Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA. The FDA has issued a complete response letter to Sobi’s application for NASP as a ...
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have ...
Hosted on MSN
Innate Pharma jumps as Sobi deal boosts secured financing for advancing rare skin cancer therapy
Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma SA IPHA on Monday forged a strategic alliance to launch a critical Phase 3 clinical trial targeting a rare form of skin cancer. The collaboration ...
Sobi will trim staff at its Stockholm manufacturing facility later this year as the company begins winding down operations there. The move comes in response to Pfizer's decision to move production of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results